Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Group Hit Over Suspect Funding (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare will halt funding to a group conducting clinical studies on a drug to treat chronic heart failure after it was found to be "double-dipping" from two sources against ministry rules. The research group took both grants-in-aid for scientific research from the health ministry and funds from the Japan Heart Foundation, which is under the ministry's jurisdiction. The group will reportedly be penalized by not being eligible for grants-in-aid for the next two years. Health ministry rules ban researchers from taking both government grants-in-aid and funds from other bodies for the same study at the same time. The research group, headed by cardiovascular expert Akira Kitabatake, an honorary professor of Hokkaido University, is researching the proper dosage of Daiichi Sankyo's drug carvedilol, a beta blocker used to treat mild to moderate congestive heart failure. Although Kitabatake asked 30 to 40 pharmaceutical companies to contribute to the foundation to fund the study, only Daiichi did so. (Click here for more

You may also be interested in...

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts